Abstract Details

Title Cost-effectiveness (CE) of fingolimod vs. intramuscular interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis (RRMS)

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 137

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Tara Nazareth (Mallinckrodt Pharmaceuticals) PRESENTER	No disclosure on file
Holly A. Shill, MD, F�鶹��ýӳ�� (Barrow Neurology Clinics)	Dr. Shill has received personal compensation in the range of $0-$499 for serving as a Consultant for Boston Scientific. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biovie. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sumitomo. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Encora. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Movement Disorders Society. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guideline Central.
	No disclosure on file
	No disclosure on file
Chen Zhao, MD	Dr. Zhao has nothing to disclose.
Rahul Sasane, PhD (Cerevel Therapeutics)	Dr. Sasane has received personal compensation for serving as an employee of Cerevel Therapeutics. Dr. Sasane has stock in Cerevel Therapeutics.

�鶹��ýӳ��